Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Captopril in bone marrow fibrosis
NCT04629651Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of captopril in myelofibrosis (MF), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Change in degree of bone marrow fibrosis by World Health Organization WHO grade at 6 months. Planned start Apr 2024; status: withdrawn.
02
Drugs
captopril
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04629651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629651.